Powered by

Cambridge Epigenetix Licenses Fundamental DNA Methylation IP from Boston Children's Hospital

Apr 28, 2017 - Business Wire

Cambridge Epigenetix, a pioneer in the development and application of epigenetic technologies, today announced that it has entered into an exclusive license agreement with Boston Children's Hospital giving access to leading-edge DNA profiling technologies, which may hold the key to improved diagnoses and treatment of many diseases, including cancer. The licensed intellectual property (IP) is based upon the early findings of Professor Anjana Rao; an expert in immunology and cancer epigenetics, fo...